Please login to the form below

Navigating the antibiotic resistance crisis

Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians navigating this complex landscape.

Antimicrobial resistance claims 5,000 lives per year in the UK and 700,000 globally – one life per minute. By 2050, it is estimated more than 10 million people will die every year of antibiotic-resistant infections, a mortality rate higher than cancer. Since the discovery of penicillin in 1928, we have used antibiotics to treat infections.

This has revolutionised medicine, preventing people from dying from infected wounds, reducing risks around surgery and curing simple ailments. However, our reliance on these drugs has led to over-use. Now bacteria have evolved to resist the power of an antibiotic attack.

We are in an arms race against the superbugs and for us to win we will need to change our approach to diagnosing and treating infections. Although scientists have continued to develop new classes of antibiotics to escape the threat of antibiotic resistance – including tetracyclines in 1945 and carbapenems in 1985, along with the new classes in development today – the bacteria have systematically produced resistance against each new class. This is driven by over-prescribing, which is in turn fuelled by a lack of rapid diagnostics that can efficiently tell doctors if a disease is bacterial or not. It is clear that simply developing novel therapies, is not a sustainable approach to overcoming antibiotic resistance.

The market is complex and to overcome the challenges of resistance we need to shape the ecosystem. In the past, therapies have been prescribed broadly and empirically, however, to tackle resistance a targeted approach is needed to allow precise treatment decisions to be made by physicians and prevent the over-use of innovative new antibiotic classes.

This new way of treating patients involves a complex array of stakeholders and will require significant behaviour change, new technology and new processes. Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher at UC Berkeley and CEO of BioAmp Diagnostics, to better undestand the physicians’ journey, their pain points and barriers, and how a new tool is helping to fuel more precise prescribing practices.

Download the full article

13th December 2018

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need
Blue Latitude Health
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need.
Blue Latitude Health
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence.
Blue Latitude Health
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry.
Blue Latitude Health
Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.
Blue Latitude Health
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.
Blue Latitude Health